Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03808961 · ClinicalTrials.gov registry record · NA
Low Dose Niacin (Vitamin B3) for Parkinson's Disease
A NA study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT03808961: Clinical Trial NA study, sponsored by VA Office of Research and Development.
NCT03808961 is a NA study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03808961, a NA study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
(1) To examine the blood, urine and spinal fluid of persons with Parkinson's to look for evidence of inflammation and; (2) whether 18 months of vitamin B3(niacin or niacinamide) supplementation may reduce the inflammation and/or improve PD motor and non-motor symptoms.
Primary Outcome
This is the Unified Parkinson's disease rating scale assessment. The investigators assess part III of the UPDRS regarding motor skills. The values reported are the averages of baseline, 6months, 12 months, and 18 months values combined for all the participants in that group. So, in the niacin and the niacinamide groups, it indicated the average of 8 values and in the control group it is the average of 12 values. A score is recorded according to the motor skills recorded ranging from 0-5 in each
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Niacinamide
- DIETARY_SUPPLEMENT Niacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2023-11-01 |
| Phase | NA |
Why NCT03808961 stopped before completion
NCT03808961 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03808961 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03808961 about?
NCT03808961 is a clinical study titled "Low Dose Niacin (Vitamin B3) for Parkinson's Disease". (1) To examine the blood, urine and spinal fluid of persons with Parkinson's to look for evidence of inflammation and; (2) whether 18 months of vitamin B3(niacin or niacinamide) supplementation may reduce the inflammation and/or improve PD motor and non-motor symptoms.
What is the current status of trial NCT03808961?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2020-01-01. Estimated completion is 2023-11-01.
What interventions are being tested in trial NCT03808961?
The interventions under investigation include: Placebo (OTHER), Niacinamide (DIETARY_SUPPLEMENT), Niacin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03808961?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03808961's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI